We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Study of Acid Reflux Therapy for Children With Asthma (SARCA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00604851
Recruitment Status : Completed
First Posted : January 30, 2008
Results First Posted : January 10, 2014
Last Update Posted : February 10, 2014
Information provided by (Responsible Party):

Study Description
Brief Summary:
Gastroesophageal reflux (GER) is frequent in children with asthma, can induce bronchspasm, and increase airway reactivity. Children with asthma are often treated for GER with drugs to supress gastric acid production. However, this treatment is expensive, and with unproven benefit. The primary objective of this study is to conduct a multi-site, randomized, clinical trial to test the hypothesis that treatment of GER with lansoprazole, an approved proton pump inhibitor, will decrease the frequency of exacerbations in children with poorly controlled asthma. The study will include 300 asthmatic children treated with inhaled corticosteroids, 6-16 years of age, with poor control defined by frequent symptoms, excessive beta agonist use, or frequent exacerbations. Participants will be randomly assigned to treatment with either lansoprazole or placebo for 6 months. The presence, severity, and relationship of GER to asthma symptoms will be determined with 24 hour esophageal pH monitoring, but randomization to treatment will not be influenced by the presence or severity of GER. The primary outcome measure is the proportion of participants who have exacerbations of asthma defined by diaries and interviews. Secondary outcome measures include asthma symptom and control scores, GER symptoms, lung function, and unscheduled health care contacts. Pre-defined subgroup analyses will examine the relationship between specific clinical features and the response to lansoprazole. Treatment response will also be evaluated with 3-hour post-dose plasma lansoprazole concentrations, and related to polymorphisms in the gene CYP2C19, the cytochrome P450 pathway, and interleukin-1 (IL-1) beta, a pro-inflammatory cytokine. Tertiary studies will determine how the magnitude of GER impacts airways inflammation, as measured by the concentrations of hydrogen ions (pH) and nitric oxide in expired breath. The results of this trial sould have a major impact on the understanding and treatment of GER in children with asthma.

Condition or disease Intervention/treatment
Asthma Drug: lansoprazole Drug: placebo

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 306 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Study of Acid Reflux Therapy for Children With Asthma
Study Start Date : September 2006
Primary Completion Date : December 2011
Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma GERD
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Lansoprazole
Participants <30 kg: 15 mg by mouth once daily; participants >= 30 kg: 30 mg by mouth once daily
Drug: lansoprazole
participants < 30 kg: 15 mg by mouth once daily; participants >= 30 kg: 30 mg by mouth once daily
Other Name: brand name Prevacid
Placebo Comparator: Placebo
Placebo medication taken by mouth once daily
Drug: placebo
placebo medication taken by mouth once daily
Other Name: No brand names

Outcome Measures

Primary Outcome Measures :
  1. Change in Asthma Control Questionnaire Score at the 24 Week Visit. [ Time Frame: Baseline and 24 weeks ]
    The Asthma Control Questionnaire contains 7 items that are scored on a 7 point scale (range is 0 to 6). The scores are then summed and divided by 7 to reveal an overall score. A lower score indicates better asthma control. The results reflect the difference in the Asthma Control Questionnaire Score between baseline (randomization visit) and 24 weeks of treatment.

Secondary Outcome Measures :
  1. Asthma Symptom and Control Scores [ Time Frame: Baseline and 24 weeks ]
  2. GER Symptoms [ Time Frame: Baseline and 24 weeks ]
  3. Lung Function [ Time Frame: Baseline and 24 weeks ]
  4. Unscheduled Heathcare Contacts [ Time Frame: Baseline and 24 weeks ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   6 Years to 16 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:Age:

  • 6-16 years
  • Asthma: Physician diagnosed asthma, mathacholine PC20<16 mg/ml, treatment with a stable dose of daily inhaled corticosteroid equivalent to 200 micrograms/day of fluticasone or greater for 8 weeks or longer
  • Poor asthma control: Use of beta-agonist for asthma symptoms twice/week or more, nocturnal awakening with asthma symptoms more than once per week, 2 or more emergency department, unscheduled physician visit, prednisone course, or hospitalizations for asthma in the past 12 months, Score of 1.5 or greater on the Juniper Scale of Recent Asthma Control
  • Absence of GERD symptoms: No symptoms clearly attributed to GER at the time of enrollment.

Exclusion Criteria:

  • Surgery: Previous anti-reflux or peptic ulcer surgery, previous tracheo-esophageal fistula repair
  • Pulmonary Function:FEV1 <60% predicted normal as measured immediately before methacholine bronchoprovocation. Methacholine bronchoprovocation limited to participants with an FEV1 >70% of predicted in accordance with FDA indication
  • Other major chronic illnesses: Any major chronic illness including but not limited to non-skin cancer, cystic fibrosis, bronchiectasis, myelomeningocele, sickle cell anemia, endocrine disease, congenital heart disease, congestive heart failure, stroke, severe hypertension, insulin-dependent diabetes mellitus, renal failure, liver disorders, immunodeficiency states, significant neurodevelopmental delay or behavioral disorders or other conditions that would interfere with participation in the study.
  • Medication Use: Anti-reflux medication (proton pump inhibitors, H2 blockers, bethanecol, metaclopromide) within 1 month; Theophylline preparations, azoles, anti-coagulants, insulin, digitalis, any investigative drug within 2 months.
  • Drug allergy: Previous adverse effects from lansoprazole, other proton pump inhibitors or methacholine challenge.
  • Non-adherence: Inability or unwillingness of the legal guardian to provide consent or inability or unwillingness of the child to provide assent. Inability to swallow study medication. Inability to perform baseline measurements. Less than 80% completion of screening period diaries. Inability to contact by telephone. Intention to move out of the areqa within 6 months. No pregnancy.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00604851

United States, Georgia
Emory Childrens Center
Atlanta, Georgia, United States, 30322
Sponsors and Collaborators
Emory University
American Lung Association
Johns Hopkins University
Nemours Children's Clinic
University of Manitoba
Washington University School of Medicine
New York Medical College
University of Vermont
Ohio State University
Baylor College of Medicine
Duke University
National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: William G Teague, MD Emory University
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Anne M Fitzpatrick PhD, Assistant Professor, Emory University
ClinicalTrials.gov Identifier: NCT00604851     History of Changes
Other Study ID Numbers: IRB00001316
5U01HL080433-02 ( U.S. NIH Grant/Contract )
SARCA ( Other Identifier: Other )
First Posted: January 30, 2008    Key Record Dates
Results First Posted: January 10, 2014
Last Update Posted: February 10, 2014
Last Verified: January 2014

Additional relevant MeSH terms:
Gastroesophageal Reflux
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action